The agency said a safety committee will determine if there’s a causal relationship between remdesivir and acute kidney injury and will update the drug’s guidance for usage accordingly.
Remdesivir’s guidance already advises physicians to monitor patients for renal impairment before and during treatment and says not to give the drug to patients with a decrease in renal function.
Kidney injury in the patients could have been caused by other factors, including diabetes, and COVID-19 itself is known to be a cause of kidney injury, the European Medicines Agency said.
The recommendations for remdesivir haven’t changed.
President Donald Trump was given remdesivir Oct. 2 after being hospitalized for COVID-19.
Read the European Medicines Agency’s full news release here.
More articles on pharmacy:
Bristol Myers Squibb acquires MyoKardia for $13B
Bipartisan bill aims to create subscription-style model for bigger antibiotic market
Drugmakers, PBMs must jointly face insulin price-fixing lawsuit, judge rules
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
